10-K: Sunshine Biopharma Reports FY2025 Results, Net Loss Widens

Sunshine Biopharma Inc. filed its annual 10-K report for the fiscal year ended December 31, 2025, detailing revenues of $36.3 million and a net loss of $5.98 million.

Summary

• Sunshine Biopharma Inc. reported revenues of $36,305,891 for the fiscal year ended December 31, 2025, an increase from $34,874,283 in 2024.
• The company experienced a net loss of $5,975,352 for fiscal year 2025, compared to a net loss of $5,134,116 in fiscal year 2024.
• General and administrative expenses increased to $18,482,706 in 2025 from $16,481,915 in 2024, largely due to a non-cash charge of $1,748,247 for the impairment of intangible assets.
• Cash and cash equivalents stood at $9,123,308 as of December 31, 2025.
• The company believes its existing cash will be sufficient to fund operations for the next 18 months, but anticipates needing additional capital.
• Sunshine Biopharma has two wholly owned subsidiaries: Nora Pharma Inc., which markets 71 generic prescription drugs in Canada, and Sunshine Biopharma Canada Inc., which sells OTC supplements.
• The company is also developing two proprietary drug candidates: K1.1 mRNA for liver cancer and SBFM-PL4, a protease inhibitor for Coronavirus infections.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the increased net loss, significant impairment charge, and ongoing need for capital, despite revenue growth in its generic segment.

Positives

• Revenue increased by approximately $1.4 million to $36,305,891 in fiscal year 2025 compared to $34,874,283 in 2024, driven by expanded sales efforts for Nora Pharma in Canada.
• Cost of sales as a percentage of revenue decreased by 3.2% in 2025 compared to 2024, attributed to lower professional allowances and wholesaler fees outside Quebec.
• Net cash used in operations significantly decreased to $5,331,073 in 2025 from $12,524,779 in 2024, due to streamlined operations and reduced inventory growth.
• The company received net proceeds of $4,748,408 from financing activities in 2025, including public offerings and warrant exercises.
• The company successfully defended against a legal claim from its former legal counsel, Andrew Telsey, with a default and final judgment in its favor.
• The company has 71 generic prescription drugs on the market in Canada through Nora Pharma and plans to launch 12 additional drugs in 2026.
• The company's SBFM-PL4 compound showed antiviral activity in SARS-CoV-2 infected cells and reduced virus load in infected mice in preclinical studies.

Negatives

• The company incurred a net loss of $5,975,352 for fiscal year 2025, an increase from $5,134,116 in 2024.
• General and administrative expenses increased by $2,000,791 in 2025, primarily due to a $1,748,247 non-cash charge for the impairment of intangible assets.
• Interest income decreased to $280,901 in 2025 from $496,003 in 2024 due to lower interest rates and reduced cash on hand.
• The company has an accumulated deficit of $75,015,126 as of December 31, 2025.
• The company relies on third-party manufacturers for approximately 75% of its generic drugs, creating potential supply chain risks.
• The company has not received regulatory approval for any of its proprietary drug candidates and does not expect significant revenues from them in the foreseeable future.
• The company faces significant competition in both the generic and proprietary drug markets.

Risks

• The company has incurred losses and may never achieve profitability, with an accumulated deficit of $75,015,126 as of December 31, 2025.
• The generic pharmaceutical business is subject to significant risks, including volatility in volumes, global supply chain issues, macroeconomic pressures, rising inflation, and disruptions from conflicts and trade restrictions.
• Nora Pharma's sales are heavily dependent on federal and provincial reimbursement frameworks in Canada, which could be adversely affected by changes in government policies.
• The company may experience delays in launching new generic products, impacting its ability to offset price erosion on existing products.
• Regulatory approval for proprietary drug candidates (K1.1 mRNA and SBFM-PL4) is uncertain, requiring extensive and costly development, preclinical testing, and clinical trials.
• The company requires significant additional funding for operations, and there is no assurance that additional financing will be available on favorable terms or at all.
• The company may be subject to litigation, which could result in significant expenses and unfavorable outcomes.
• The company relies on key personnel, including Dr. Steve N. Slilaty, and the loss of such personnel could delay research and development efforts.
• Product liability risks are inherent in the pharmaceutical business, and current insurance may not provide adequate coverage.
• The company faces risks related to hazardous materials and environmental laws.
• Third-party manufacturers may not be able to scale up production of approved product candidates, potentially delaying commercialization.
• The company may be unable to establish adequate sales and marketing capabilities for its proprietary drug candidates.
• Market acceptance of proprietary drug candidates, even if approved, is not guaranteed and depends on various factors including efficacy, safety, pricing, and reimbursement.
• Preclinical study results are not necessarily predictive of future clinical trial outcomes, and product candidates may fail to demonstrate safety and efficacy.
• The company faces significant competition from larger pharmaceutical companies with greater resources.
• Adverse events affecting the company's intellectual property rights could impair its ability to commercialize products.
• Confidentiality agreements may not adequately prevent disclosure of trade secrets, and enforcing intellectual property rights can be difficult and costly.
• Rapid growth could impose a significant burden on administrative and operational resources.
• The failure of suppliers to provide quality materials in sufficient quantities and at favorable prices could adversely affect operations.
• The company is subject to the effects of adverse publicity, which could negatively impact sales and revenues.
• Manufacturing and third-party fulfillment activities are subject to operational risks.
• Dependence on a concentrated base of finished goods suppliers increases the risk of product interruption.
• The price and trading volume of the company's common stock are volatile, and it may face challenges in meeting Nasdaq listing requirements, including the minimum bid price.
• The company does not intend to pay dividends for the foreseeable future.
• The board of directors has the authority to create new series of preferred stock, which could adversely affect the rights of common stockholders.
• Future stock offerings or the issuance of stock upon exercise of warrants may dilute existing shareholders' ownership.

Future Outlook

The company believes its existing cash will be sufficient to fund its operations for the next 18 months. However, it anticipates needing to raise additional capital in the future to expand its generic pharmaceutical operations, and there is no assurance that such capital will be available on acceptable terms or at all. The company expects initiatives implemented in January 2026 to reduce general and administrative expenses by approximately $2 million to $3 million in 2026.

Management Comments

• The increase in revenue was the result of expansion of Nora Pharma sales efforts in the Provinces of Quebec, Ontario, Alberta, and British Columbia.
• The decrease in the cost of sales in 2025 was largely due to lower professional allowances incurred on the sale of products outside the Province of Quebec.
• The increase in General and Administrative expenses in 2025 is primarily attributable to a non-cash charge of $1,748,247 related to the impairment of intangible assets.
• In January 2026, we implemented initiatives to reduce our general and administrative expenses and better align our cost structure with the Company's objective of achieving profitability in the near term.
• We believe our existing cash will be sufficient to fund our operations for the next 18 months.
• We have no committed sources of capital and we anticipate that we will need to raise additional capital in the future to expand our generic pharmaceutical operations.
• Our management, including our CEO and CFO, concluded that our disclosure controls and procedures were effective as of December 31, 2025.
• Our management, including our CEO and CFO, evaluated the effectiveness of our internal control over financial reporting as of December 31, 2025, and they concluded that our internal control over financial reporting was effective.

Industry Context

StockSavvy.ai notes that Sunshine Biopharma operates in the highly competitive Canadian generic pharmaceutical market, valued at approximately $10.4 billion USD in 2024 and projected to grow significantly. While the company has shown strong year-over-year sales growth, it faces intense competition from over 35 players, with the top three holding a 50% market share. The company's proprietary drug development in oncology and antivirals places it in a sector with substantial R&D investment and competition from major global pharmaceutical firms.

Comparison to Industry Standards

• The Canadian generic pharmaceutical market was valued at approximately $10.4 billion USD in 2024 and is expected to grow to $19.7 billion USD by 2033 (IMARC Group).
• Generic pharmaceutical companies produce and deliver more than 70% of prescribed medicines in Canada.
• The top 3 generic players in the Canadian market hold approximately 50% of the total market share.
• Sunshine Biopharma's net loss of $5.98 million in FY2025, while significant, should be viewed in the context of its ongoing R&D investments and its position as a smaller player in a large market.
• The company's revenue growth of approximately $1.4 million in FY2025 is positive but needs to be sustained to outpace market growth and competition.

Legal Proceedings

• The company received a demand letter from the attorneys of Mr. Andrew Telsey, its former legal counsel, asserting an employment agreement and demanding $3,645,750. The company filed a complaint seeking a declaratory judgment that the agreement was not legally binding, and the court granted a default and final judgment in favor of the company.
• The company terminated the employment of Mr. Malek Chamoun, president of Nora Pharma. His attorneys sent a demand letter for $5,300,000 USD. The company considers these demands unfounded and intends to defend itself vigorously. This remaining earnout amount is currently in dispute.

Related Party Transactions

• The company sold shares of Series B Preferred Stock to Dr. Steve N. Slilaty, its CEO, for $0.10 per share on February 8, 2024, and March 4, 2024.
• Compensation paid to officers included amounts paid to Advanomics Corporation, a company controlled by Dr. Slilaty.

Stakeholder Impact

• Shareholders may experience dilution due to potential future capital raises and stock issuances.
• The company's continued net losses and need for external financing could impact investor confidence.
• Employees may be affected by cost-reduction initiatives aimed at achieving profitability.
• Customers (pharmacies, wholesalers) may benefit from the planned launch of 12 new generic drugs in 2026.
• Suppliers may face continued pressure on pricing and potential supply chain disruptions.

Next Steps

• Implement initiatives to reduce general and administrative expenses by approximately $2 million to $3 million in 2026.
• Continue to expand Nora Pharma's sales efforts in Canadian provinces.
• Anticipate launching 12 additional generic drugs during the remainder of 2026.
• Continue research and development for K1.1 mRNA (oncology) and SBFM-PL4 (antiviral) drug candidates.
• Seek additional capital to fund future operations and expansion.

Key Dates

Recommendation

Sunshine Biopharma shows revenue growth in its established generic drug business, but this is overshadowed by increasing net losses, significant intangible asset impairment, and a clear need for future capital raises. The proprietary drug development pipeline remains in early stages with no guarantee of regulatory approval. While the company has successfully defended against legal claims, the overall financial picture and competitive landscape warrant a cautious 'hold' approach.

Keywords

Sunshine Biopharma, Form 10-K, Annual Report, Generic Drugs, Pharmaceuticals, Drug Development, Oncology, Antivirals, Nora Pharma, SEC Filing, Financial Results, Net Loss, Revenue, Intellectual Property, Regulatory Approval, Nasdaq, SBFM